Optipharm.CO.LTD Market Cap ($45.68 Million)
Market Cap & Net Worth: Optipharm.CO.LTD (153710)
Optipharm.CO.LTD market cap. Optipharm.CO.LTD (KQ:153710) has a market capitalization of $45.68 Million (₩67.41 Billion) as of November 5, 2026. Listed on the KQ stock exchange, this Korea-based company holds position #22059 globally and #1372 in its home market, demonstrating a 5.63% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Optipharm.CO.LTD's stock price ₩4595.00 by its total outstanding shares 14669958 (14.67 Million). Also see 153710 operating cash flow for how efficiently the company converts equity into cash flow.
Optipharm.CO.LTD Market Cap History (2018–2026)
Optipharm.CO.LTD market cap history from 2018 to 2026. Data shows change from $91.36 Million to $45.68 Million (-10.99% CAGR). Check Optipharm.CO.LTD (153710) share price today for real-time trading data and today's change.
Index Memberships
Optipharm.CO.LTD is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
Kosdaq Composite Index
KOSDAQ
|
$207.23 Billion | 0.02% | #650 of 1384 |
|
Kosdaq Composite Index
KQ11
|
$207.23 Billion | 0.02% | #650 of 1384 |
Weight: Optipharm.CO.LTD's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Optipharm.CO.LTD Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Optipharm.CO.LTD's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore 153710 shareholders equity momentum to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
0.00x
Optipharm.CO.LTD's market cap is 0.00 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2018 | $91.36 Million | $13.96 Billion | -$604.46 Million | 0.01x | N/A |
| 2019 | $89.87 Million | $13.65 Billion | -$655.33 Million | 0.01x | N/A |
| 2020 | $151.11 Million | $13.05 Billion | -$2.35 Billion | 0.01x | N/A |
| 2021 | $93.55 Million | $14.26 Billion | -$3.08 Billion | 0.01x | N/A |
| 2022 | $69.69 Million | $16.01 Billion | -$2.04 Billion | 0.00x | N/A |
| 2023 | $69.89 Million | $17.37 Billion | -$2.44 Billion | 0.00x | N/A |
| 2024 | $46.18 Million | $19.64 Billion | -$2.36 Billion | 0.00x | N/A |
| 2025 | $50.70 Million | $22.34 Billion | -$2.50 Billion | 0.00x | N/A |
Competitor Companies of 153710 by Market Capitalization
Companies near Optipharm.CO.LTD in the global market cap rankings as of November 5, 2026. Also see Optipharm.CO.LTD balance sheet assets for a full breakdown of the balance sheet.
Key companies related to Optipharm.CO.LTD by market ranking:
- Thermo Fisher Scientific Inc (NYSE:TMO): Ranked #86 globally with a market cap of $224.59 Billion USD.
- Danaher Corporation (NYSE:DHR): Ranked #138 globally with a market cap of $165.94 Billion USD.
- Natera Inc (NASDAQ:NTRA): Ranked #479 globally with a market cap of $56.33 Billion USD.
- WuXi AppTec Co Ltd (SHG:603259): Ranked #505 globally with a market cap of $53.86 Billion USD ( CN¥368.05 Billion CNY).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #86 | Thermo Fisher Scientific Inc | NYSE:TMO | $224.59 Billion | $706.16 |
| #138 | Danaher Corporation | NYSE:DHR | $165.94 Billion | $234.93 |
| #479 | Natera Inc | NASDAQ:NTRA | $56.33 Billion | $391.03 |
| #505 | WuXi AppTec Co Ltd | SHG:603259 | $53.86 Billion | CN¥148.81 |
Market Capitalization of Optipharm.CO.LTD (2018–2026)
Market capitalization of Optipharm.CO.LTD from 2018 to today. Between 2018 and today, Optipharm.CO.LTD's market cap moved from $91.36 Million to $ 45.68 Million, with a yearly change of -10.99%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | ₩45.68 Million | -9.90% |
| 2025 | ₩50.70 Million | +9.80% |
| 2024 | ₩46.18 Million | -33.93% |
| 2023 | ₩69.89 Million | +0.29% |
| 2022 | ₩69.69 Million | -25.50% |
| 2021 | ₩93.55 Million | -38.09% |
| 2020 | ₩151.11 Million | +68.14% |
| 2019 | ₩89.87 Million | -1.63% |
| 2018 | ₩91.36 Million | -- |
End of Day Market Cap According to Different Sources
On Nov 5th, 2026 the market cap of Optipharm.CO.LTD was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $45.68 Million USD |
| MoneyControl | $45.68 Million USD |
| MarketWatch | $45.68 Million USD |
| marketcap.company | $45.68 Million USD |
| Reuters | $45.68 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Optipharm.CO.LTD
Optipharm.CO.,LTD operates as a biomedical solution provider in South Korea. It also engages in animal disease diagnosis, animal medicine, bacteriophage, Medipig, xenogenic organs, VLP vaccines, xenotransplantation, and other optipharm products, as well as veterinary drug for feed additives and laboratory animal Medipig business. The company was formerly known as Optiparm Solution Co., Ltd. and c… Read more